<DOC>
	<DOCNO>NCT01192854</DOCNO>
	<brief_summary>Randomized , double blind parallel group , positive control , multi-center trial . Patients randomize 1:1 ratio group A group B</brief_summary>
	<brief_title>An Study Efficacy Safety Clevudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patients 18 65 , inclusive . 2 . All male female reproductiveaged subject use reliable appropriate contraceptive method entrance screen least 3 month within end study . 3 . Hepatitis B virus Early Antigen ( HBeAg ) positive patient HBV DNA &gt; 1 x 105 copies/ml , HBeAg negative patient HBV DNA &gt; 1 x 104 copies/ml within 30 day baseline . 4 . Absolute neutrophil count &gt; 1500 /mm3 . 5 . Alpha fetoprotein within normal laboratory limit screening . 6 . Normal electrocardiogram ( ECG ) clinically nonsignificant change screen . 7 . Able participate willing give write informed consent start therapy . 8 . Able willing comply study assessment restriction . 9 . Normal renal function take Adefovir without dose modification ; Creatinine clearance must &gt; 50 ml/min ( base CockcroftGault equation . Exclusion criteria 1 . Subjects coinfected human immunodeficiency virus ( HIV ) , hepatitis A virus ( HAV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) hepatitis E virus 2 . Patients previously currently treat approve investigational nucleoside ( e.g . : lamivudine , adefovir . entecavir , lobucavir , famciclovir , tenofovir , telbivudine ) duration . 3 . Other chronic hepatic disease . e.g . chronic alcoholism . Wilson 's disease . 4 . Poorly control type I type 2 diabetes mellitus 5 . Donation loss 400 ml blood within 60 day baseline . 6 . Known serious allergy nucleoside/nucleotide analog . 7 . Subjects pregnant , nursing , unwilling use appropriate form contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Clevudine</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>chronic hepatitis B</keyword>
</DOC>